Literature DB >> 30451751

Hemorrhoidal Disease Symptom Score and Short Health ScaleHD: New Tools to Evaluate Symptoms and Health-Related Quality of Life in Hemorrhoidal Disease.

Håvard D Rørvik1, Karl Styr1, Lars Ilum1, Grant L McKinstry1, Tove Dragesund2, André H Campos1, Birgitte Brandstrup1,3, Gunnar Olaison1,3.   

Abstract

BACKGROUND: There are no adequately validated tools to evaluate symptoms or disease-specific health-related quality of life in hemorrhoidal disease.
OBJECTIVE: The purpose of this study was to assess validity, reliability, and responsiveness of a symptom score of patient-reported pain, itching, bleeding, soiling, and prolapse (Hemorrhoidal Disease Symptom Score). In addition, the study set out to assess reliability and responsiveness of an instrument to measure health-related quality of life in patients with hemorrhoids (Short Health ScaleHD), with 1 item in its 4 dimensions: symptom load, functional status, disease-specific worries, and general well-being.
DESIGN: This was a cross-sectional (validity and reliability) and longitudinal (responsiveness) study. SETTINGS: The study was conducted at a single center. PATIENTS: Cohort 1 included 295 patients with hemorrhoids to study validity and 60 patients with test-retest scores to study reliability. Cohort 2 included 128 and 121 patients operated for hemorrhoids to study responsiveness of the Hemorrhoidal Disease Symptom Score and the Short Health ScaleHD. MAIN OUTCOME MEASURES: The study evaluated validity, reliability, and responsiveness. Patient-reported symptom load on a 7-point Likert scale was used as comparator, and receiver operating characteristics curve assessed discriminative validity. Interclass correlation assessed reliability. Receiver operating characteristics curve assessed responsiveness, meaning the ability to discriminate between patients with and without improvement after surgery.
RESULTS: The Hemorrhoidal Disease Symptom Score demonstrated the ability to discriminate between patients reporting high or low symptom load (area under the curve = 0.786 (95% CI, 0.725-0.848)). The Hemorrhoidal Disease Symptom Score and the Short Health ScaleHD demonstrated adequate reliability and responsiveness, with interclass correlation of 0.822 (95% CI, 0.715-0.891) and 0.763 (95% CI, 0.634-0.851) and area under the curve of 0.843 (95% CI, 0.756-0.929) and 0.840 (95% CI, 0.752-0.929). LIMITATIONS: We had no gold standard comparator to assess validity and responsiveness.
CONCLUSIONS: The findings suggest that the Hemorrhoidal Disease Symptom Score is valid, reliable, and responsive and that the Short Health ScaleHD is reliable and responsive. Used together, these tools provide a good overview of symptoms and their impact on patient well-being. See Video Abstract at http://links.lww.com/DCR/A770.

Entities:  

Mesh:

Year:  2019        PMID: 30451751     DOI: 10.1097/DCR.0000000000001234

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  16 in total

1.  Minimal open hemorrhoidectomy.

Authors:  H D Roervik; A Heiner Campos; L Ilum; K F Herlak Styr; G K McKinstrey; B Brandstrup; G Olaison
Journal:  Tech Coloproctol       Date:  2019-02-06       Impact factor: 3.781

2.  Results of the double-blind randomized controlled trial comparing laser hemorrhoidoplasty with sutured mucopexy and excisional hemorrhoidectomy.

Authors:  Tomas Poskus; Donatas Danys; Gabija Makunaite; Antanas Mainelis; Saulius Mikalauskas; Eligijus Poskus; Valdemaras Jotautas; Audrius Dulskas; Eugenijus Jasiunas; Kestutis Strupas
Journal:  Int J Colorectal Dis       Date:  2020-01-08       Impact factor: 2.571

3.  Modified rubber band ligation for treatment of grade II/III hemorrhoids: clinical efficacy and safety evaluation-a retrospective study.

Authors:  Jiazi Yu; Jie Zhong; Tao Peng; Liangbin Jin; Leibin Shen; Mian Yang
Journal:  BMC Surg       Date:  2022-06-20       Impact factor: 2.030

4.  The REALISE score: a new statistically validated scoring system to assess the severity of anal fissures.

Authors:  A Picciariello; P Lobascio; L Spazzafumo; M Rinaldi; R Dibra; G Trigiante; R Laforgia; A Pezzolla; D F Altomare
Journal:  Tech Coloproctol       Date:  2021-05-13       Impact factor: 3.781

5.  Is the Goligher classification a valid tool in clinical practice and research for hemorrhoidal disease?

Authors:  L Dekker; I J M Han-Geurts; U Grossi; G Gallo; R Veldkamp
Journal:  Tech Coloproctol       Date:  2022-02-09       Impact factor: 3.699

Review 6.  Consensus statement of the Italian society of colorectal surgery (SICCR): management and treatment of hemorrhoidal disease.

Authors:  G Gallo; J Martellucci; A Sturiale; G Clerico; G Milito; F Marino; G Cocorullo; P Giordano; M Mistrangelo; M Trompetto
Journal:  Tech Coloproctol       Date:  2020-01-28       Impact factor: 3.781

7.  Improvement in quality of life among Sri Lankan patients with haemorrhoids after invasive treatment: a longitudinal observational study.

Authors:  S Y J Keong; H K Tan; M D Lamawansa; J C Allen; Z L Low; T Østbye
Journal:  BJS Open       Date:  2021-03-05

8.  Efficacy and Tolerability of a New Formulation in Rectal Ointment Based on Zn-L-Carnosine (Proctilor®) in the Treatment of Haemorrhoidal Disease.

Authors:  Renato Pietroletti; Antonio Giuliani; Alberto Buonanno; Antonella Mattei; Fabiana Fiasca; Gaetano Gallo
Journal:  Front Surg       Date:  2022-03-24

9.  Polidocanol foam sclerotherapy in the treatment of hemorrhoidal disease in patients with bleeding disorders: a multicenter, prospective, cohort study.

Authors:  P Salgueiro; A Rei; M Garrido; B Rosa; A M Oliveira; T Pereira-Guedes; S Morais; F Castro-Poças
Journal:  Tech Coloproctol       Date:  2022-02-25       Impact factor: 3.699

10.  Classification and guidelines of hemorrhoidal disease: Present and future.

Authors:  Michele Rubbini; Simona Ascanelli
Journal:  World J Gastrointest Surg       Date:  2019-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.